Reinstate PA Medicaid Coverage of GLP-1s for Obesity

Background: After years of advocacy efforts, Pennsylvania Medical Assistance (Medicaid) coverage for these life saving medications began in 2023. In January 2026, coverage of GLP-1s for the treatment of obesity was ended due to budget concerns.

Data shows that the cost of obesity medications is not the root of the budget problem and only a small fraction of the overall spend on the class of GLP-1s. Obesity is a complex chronic disease and people living with obesity have a right to FDA-approved medications — in the same fashion as diabetes, heart disease or hypertension.

Take Action Now: Use OAC’s advocacy tool below to tell Pennsylvania’s Governor and lawmakers to reinstate coverage of GLP-1s for the treatment of obesity.

It’s Easy to Advocate! Use our easy automated message generator below to get started. You’ll find an easy to use template letter to get you started, and we encourage you to include your story and thoughts before sending.